Epigenetic mechanisms in non-small cell lung cancer therapy and chemoresistance

被引：0

作者：

Xu, Ying ^{[1
]}

Meng, Yang ^{[2
,3
]}

Xu, Yongfeng ^{[4
,5
]}

Han, Junhong ^{[2
,3
]}

Zhu, Qing ^{[1
]}

机构：

[1] Sichuan Univ, West China Hosp, Canc Ctr, Div Abdominal Tumor Multimodal Treatment, 37 Guoxue Alley, Chengdu 610041, Sichuan, Peoples R China

[2] Sichuan Univ, West China Hosp, Canc Ctr, Dept Biotherapy, Chengdu 610041, Peoples R China

[3] Sichuan Univ, West China Hosp, Frontiers Sci Ctr Dis Related Mol Network, State Key Lab Biotherapy, Chengdu 610041, Peoples R China

[4] Rhein Westfal TH Aachen, Uniklin RWTH Aachen, D-52074 Aachen, Germany

[5] Rhein Westfal TH Aachen, Helmholtz Inst Biomed Engn, D-52074 Aachen, Germany

来源：

BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER | 2025年 / 1880卷 / 04期

基金：

中国国家自然科学基金; 中国博士后科学基金;

关键词：

Epigenetics; Non-small cell lung cancer; Chemoresistance; Mechanism; Molecular target; PROMOTES CISPLATIN RESISTANCE; ZESTE HOMOLOG 2; ADENOCARCINOMA CELLS; DNA METHYLATION; TUMOR-SUPPRESSOR; POOR-PROGNOSIS; DOCETAXEL CHEMORESISTANCE; HISTONE ACETYLATION; EARLY EVENT; EXPRESSION;

D O I：

10.1016/j.bbcan.2025.189356

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

Epigenetic mechanisms play a crucial role in cancer development and progression, encompassing DNA methylation, chromatin organization, histone modifications, and noncoding RNA regulation. Lung cancer is a major cause of cancer-related deaths worldwide, with non-small cell lung cancer (NSCLC) accounting for approximately 85 % of all cases. Despite advances in detection and treatment, the prognosis for NSCLC patients remains poor, largely attributable to the development of chemoresistance. Chemoresistance is a key driver of cancer recurrence and metastasis. Targeting epigenetic modifications emerges as a promising strategy to reverse chemoresistance. Elucidating the mechanisms by which epigenetic modulation influences chemoresistance in NSCLC, coupled with the development of drugs to counteract this phenomenon, offers significant potential to improve the survival rates and quality of life for NSCLC patients. In this review, we comprehensively summarize the contributions of various epigenetic regulators to chemoresistance in NSCLC. We also explore the relationship between distinct epigenetic modifications and chemoresistance in NSCLC and discuss the translational potential of these findings into clinical therapies.

引用

页数：22

共 298 条

[1] Epigenetic Therapeutics: A New Weapon in the War Against Cancer [J].